Aetna modified CPB 0307, its Parkinson's disease coverage policy, effective February 25, 2026. Here's what billing teams need to know.
Aetna, a CVS Health company, updated Clinical Policy Bulletin 0307 governing Parkinson's disease (PD) diagnosis and treatment. This update affects a wide range of CPT and HCPCS codes — from DBS and pallidotomy procedures to newer infusion pumps, neurofilament biomarkers, and experimental designations for alpha-synuclein immunotherapy and robot-assisted gait training. If your practice bills for neurology, movement disorders, DME, or neuropsychological testing, this policy change touches your revenue cycle.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Parkinson's Disease — CPB 0307 |
| Policy Code | CPB 0307 |
| Change Type | Modified |
| Effective Date | February 25, 2026 |
| Impact Level | High |
| Specialties Affected | Neurology, movement disorders, DME suppliers, neuropsychology, nuclear medicine, radiation oncology |
| Key Action | Audit charge capture for infusion pump DME codes, DBS surgical codes, and newly experimental/investigational designations before billing claims against this updated policy |
Aetna Parkinson's Disease Coverage Criteria and Medical Necessity Requirements 2026
CPB 0307 Aetna is one of the more complex neurology policies on the books. It covers the full diagnostic and treatment spectrum for PD — and it draws hard lines between covered, investigational, and unproven services.
Diagnosis
Aetna considers several diagnostic approaches medically necessary when the diagnosis of PD is in doubt or requires differentiation from other conditions.
A levodopa or apomorphine challenge meets medical necessity when confirming a PD diagnosis. Olfactory testing — specifically the University of Pennsylvania Smell Identification Test (UPSIT) or "Sniffin' Sticks" — is covered to differentiate PD from progressive supranuclear palsy and cortico-basal degeneration. Neuropsychological testing for PD diagnosis is also covered. Bill that under CPT 96132, 96133, or 96146 depending on how the evaluation is structured.
SPECT scanning (CPT 78607, DaTSCAN / Ioflupane I-123 injection) is covered to distinguish PD from essential tremor. Full stop. It is not covered for distinguishing PD from other parkinsonian syndromes, and it is not covered for monitoring PD progression. If you're billing 78607 for anything other than the ET differentiation indication, expect a claim denial.
Brain MRI — CPT 70551, 70552, 70553 — appears in this policy's code set. The source groups these codes under the genetic and biomarker section rather than the covered procedures section. Document the clinical indication carefully and confirm coverage status with Aetna directly before submitting claims.
Non-Surgical Treatment: Duopa and Vyalev Infusion Pumps
This is where the Aetna Parkinson's disease coverage policy gets operationally important for your billing team. Two infusion systems now have explicit medical necessity criteria.
Carbidopa/levodopa enteral suspension (Duopa) has explicit medical necessity criteria that must be documented and met for coverage. The prescriber must be a neurologist or specialist in PD treatment. Initial coverage requires all three of these: the member is levodopa-responsive with defined "on" periods; the member has "off" periods of at least three hours per day despite optimization; and the member had an inadequate response or intolerable adverse event with oral carbidopa-levodopa plus at least one additional agent (a COMT inhibitor like entacapone or tolcapone, a dopamine agonist like pramipexole or ropinirole, or an MAO-B inhibitor like selegiline or rasagiline). Prior authorization is typically required for criteria-based coverage of this type — confirm Aetna's current PA requirements before initiating therapy.
The CADD-Legacy 1400 portable infusion pump is covered DME for members who qualify for Duopa. The Vyafuser ambulatory infusion pump (for foscarbidopa/foslevodopa, brand name Vyalev) is separately covered as DME for members who meet Vyalev criteria. Note that foscarbidopa/foslevodopa (Vyalev) injection itself runs through the pharmacy benefit — not medical — so your reimbursement path for the drug is separate from the DME pump.
Surgical Treatment: Pallidotomy and Deep Brain Stimulation
Pallidotomy is covered for idiopathic PD when four criteria are all met: the member tried and failed medical therapy (motor fluctuations, "wearing off," unpredictable on/off, or Sinemet-induced dyskinesia); the member exhibits 2 of 4 major symptoms (bradykinesia, tremor, rigidity, and gait disturbance); the member has a history of positive response to dopaminergic replacement therapy; and a movement disorder neurologist has confirmed all reasonable pharmacotherapy options have failed.
Pallidotomy is explicitly considered of no proven value in atypical or Parkinson's-plus presentations. Document idiopathic PD clearly before billing CPT 61720 or 61735 for this indication.
Deep brain stimulation (DBS) — billed under CPT 61863, 61864, 61867, 61868 — is covered when criteria are met. Aetna's DBS criteria are detailed, so confirm your neurosurgeon's documentation aligns with this policy before February 25, 2026. MRgFUS (CPT 0398T, HCPCS C9734) for stereotactic ablation is a different story — see the exclusions section below.
Aetna Parkinson's Disease Exclusions and Non-Covered Indications
This section is where billing teams need to pay close attention. The CPB 0307 Aetna coverage policy lists a substantial number of experimental, investigational, and unproven designations. Billing these will generate denials.
Alpha-synuclein immunotherapy — experimental and unproven. The policy groups CPT codes 0398T, 38232, 38240, 38241, 42400, 61850, 61860, 63650, 63655, 63661–63664, 63685, 63688, 64760, 90867–90869, 92270, 93660, 93890, 95961, 95962, 95970–95972, and 99183 under this investigational umbrella for alpha-synuclein immunotherapy. Some of these codes (like 90867–90869 for repetitive TMS and 63650/63655 for spinal neurostimulators) have covered uses in other contexts, so the group label matters. Document the specific indication.
Robot-assisted gait training — experimental and unproven. This applies to the same CPT code grouping listed above.
SPECT scanning for non-ET indications — as noted above, using 78607 for anything other than differentiating PD from essential tremor is not covered.
Genetic and biomarker testing — several codes in this policy are explicitly not covered for specific PD indications. CPT 81401 is listed as not covered for urinary LRRK2 phosphorylation. Apolipoprotein E (APOE) testing under CPT 82172 is not covered. A number of salivary biomarker codes — 82013 (acetylcholinesterase), 82530, 82533 (cortisol) — sit in the genetic testing group with coverage contingent on indication.
Neurofilament light chain tests — CPT 0361U, 0443U, 0547U, and 83884 appear in the code set. These newer quantitative NfL assays are included in the policy but fall under the same investigational grouping as other experimental biomarker testing for PD.
Topical and hyperbaric oxygen — CPT 99183, A4575, and E0446 are in the code set, grouped under experimental designations. Don't bill these for PD indications.
Vagotomy (CPT 64760) — listed under the experimental grouping. Don't bill abdominal vagotomy as a PD treatment.
SMPD1 gene analysis (CPT 81330) — grouped under the genetic testing section. Coverage is condition-specific, so verify your indication maps to the covered criteria.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Levodopa/apomorphine challenge for diagnosis | Covered | — | Diagnosis in doubt required |
| Olfactory testing (UPSIT / Sniffin' Sticks) | Covered | — | For differentiation from PSP and CBD |
| Neuropsychological testing | Covered | CPT 96132, 96133, 96146 | PD diagnosis evaluation |
| SPECT (DaTSCAN) to distinguish PD from essential tremor | Covered | CPT 78607 | Covered for ET differentiation only |
| SPECT for distinguishing PD from other parkinsonian syndromes | Not Covered | CPT 78607 | Experimental/investigational for this use |
| SPECT for monitoring PD progression | Not Covered | CPT 78607 | Experimental/investigational for this use |
| Brain MRI to differentiate PD | Listed — verify indication/group | CPT 70551, 70552, 70553 | Source groups these under genetic/biomarker section, not covered procedures; confirm with Aetna before billing |
| Duopa (carbidopa/levodopa enteral suspension) | Covered (criteria) | — | Medical necessity criteria must be documented; confirm PA requirements with Aetna; neurologist prescriber required; 3-criteria threshold |
| CADD-Legacy 1400 infusion pump (DME) | Covered (criteria) | — | Covered if member qualifies for Duopa |
| Vyafuser pump for foscarbidopa/foslevodopa (DME) | Covered (criteria) | — | Drug (Vyalev) goes through pharmacy benefit |
| Pallidotomy for idiopathic PD | Covered (criteria) | CPT 61720, 61735 | All four surgical criteria must be met |
| Pallidotomy for atypical / Parkinson's-plus | Not Covered | CPT 61720, 61735 | No proven value |
| DBS implantation | Covered (criteria) | CPT 61863, 61864, 61867, 61868 | Criteria-driven; document fully |
| MRgFUS stereotactic ablation | Experimental | CPT 0398T, HCPCS C9734 | Alpha-synuclein immunotherapy group |
| Robot-assisted gait training | Experimental | CPT 0398T and related | Not covered for PD |
| Alpha-synuclein immunotherapy | Experimental | Multiple CPT codes | Full code list in affected codes table |
| Repetitive TMS (rTMS) | Experimental | CPT 90867, 90868, 90869 | Grouped under experimental for PD |
| LRRK2 urinary phosphorylation (CPT 81401) | Not Covered | CPT 81401 | Explicitly excluded |
| APOE testing (CPT 82172) | Not Covered | CPT 82172 | Explicitly excluded |
| Salivary biomarkers (acetylcholinesterase, cortisol) | Experimental | CPT 82013, 82530, 82533 | Grouped under genetic/biomarker section |
| Neurofilament light chain testing | Experimental | CPT 0361U, 0443U, 0547U, 83884 | Investigational for PD per current policy |
| Hyperbaric oxygen therapy | Experimental | CPT 99183, HCPCS A4575, E0446 | Not covered for PD indication |
| Growth hormone stimulation panel | Listed — verify indication/group | CPT 80428 | Source places this in the genetic/biomarker group, not the covered procedures group; verify indication before billing |
| Cannabinoids testing | Listed | CPT 80349–80352 | Related codes listed; verify coverage |
| Vagotomy | Experimental | CPT 64760 | Not covered as PD treatment |
Aetna Parkinson's Disease Billing Guidelines and Action Items 2026
| # | Action Item |
|---|---|
| 1 | Audit your charge capture for CPT 78607 before February 25, 2026. Check every active PD claim or pending order using this SPECT code. Confirm the documented indication is essential tremor differentiation. Any other indication will generate a claim denial under this coverage policy. |
| 2 | Document all Duopa medical necessity criteria before initiating therapy. If your practice initiates Duopa therapy, confirm your process captures all three coverage criteria: levodopa responsiveness with defined "on" periods, "off" periods of at least three hours despite optimization, and documented failure of oral carbidopa-levodopa plus one qualifying adjunct agent. Missing any of these means a denial. Prior authorization is typically required for this type of criteria-based coverage — confirm Aetna's current PA requirements directly before submitting. |
| 3 | Separate the Vyalev drug benefit from the DME pump benefit. Bill the Vyafuser ambulatory pump under the medical/DME benefit. Route the foscarbidopa/foslevodopa drug itself through the pharmacy benefit. Submitting the drug as medical will cause a denial or redirect. |
| 4 | Flag the experimental code groups in your billing system. The alpha-synuclein immunotherapy and robot-assisted gait training experimental groups include CPT codes that have covered uses elsewhere — including 63650, 63655, 90867, 90868, 90869, and others. Label these with a warning that triggers documentation review before submission for a PD indication. |
| 5 | Document idiopathic PD explicitly for pallidotomy and DBS claims. CPT 61720 and 61735 are not covered for atypical parkinsonism or Parkinson's-plus. If the diagnosis code on the claim suggests an atypical presentation, Aetna will deny the surgical claim. Make sure your ICD-10 coding and clinical documentation align. |
| 6 | Review neurofilament light chain test orders. CPT 0361U, 0443U, 0547U, and 83884 are all in this policy's code set under experimental groupings. If your neurology team is ordering these as PD progression biomarkers, they will not be reimbursed under this policy. Talk to your ordering physicians about documentation and patient financial responsibility disclosures. |
| 7 | Check your DME billing for neurostimulator hardware codes — and confirm with Aetna directly. HCPCS C1607, C1767, C1778, C1787, C1816, C1820, C1822, C1883, and C1897 are all in scope. These codes are expected to be covered when the underlying DBS surgical criteria are met, but the source data groups all HCPCS codes together under a single group label rather than explicitly separating covered from non-covered codes in the table structure. Confirm individual HCPCS code coverage status with Aetna before billing to avoid surprises. |
| 8 | Verify your Brain MRI coding before billing against this policy. CPT 70551, 70552, and 70553 appear in this policy's code set, but the source groups them under the genetic and biomarker section — not the covered procedures section. Until you confirm coverage status with Aetna, treat these as "verify indication" codes and document the clinical rationale fully. |
If your practice handles a high volume of Parkinson's cases across multiple service lines — neurology, neurosurgery, neuropsychology, nuclear medicine, and DME — loop in your compliance officer before the effective date of February 25, 2026. The scope of this policy is wide, and the interaction between covered surgical codes and experimental groupings with overlapping codes creates real denial risk.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Parkinson's Disease Under CPB 0307
Covered CPT Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 61720 | CPT | Creation of lesion by stereotactic method, including burr hole(s) and localizing/recording techniques (globus pallidus or thalamus) |
| 61735 | CPT | Subcortical structure(s) other than globus pallidus or thalamus |
| 61863 | CPT | Twist drill, burr hole, craniotomy, or craniectomy with stereotactic implantation of neurostimulator electrode array, subcortical |
| +61864 | CPT | Each additional array (add-on to 61863) |
| 61867 | CPT | Twist drill, burr hole, craniotomy, or craniectomy with stereotactic implantation of neurostimulator electrode array, subcortical, with MRI or CT |
| +61868 | CPT | Each additional array (add-on to 61867) |
| 78607 | CPT | Brain imaging, tomographic (SPECT) — to distinguish PD from essential tremor |
| 96132 | CPT | Neuropsychological testing evaluation services by physician or other qualified health care professional |
| 96133 | CPT | Neuropsychological testing evaluation services, each additional hour |
| 96146 | CPT | Psychological or neuropsychological test administration with single automated, standardized instrument |
Other Related Codes — Verify Indication Before Billing
These codes appear in the CPB 0307 policy code set but are grouped under the genetic/biomarker section in the source data rather than the covered procedures section. Coverage status depends on the specific clinical indication. Confirm with Aetna before submitting claims.
| Code | Type | Description | Notes |
|---|---|---|---|
| 70551 | CPT | MRI brain (including brain stem), without contrast | Source groups under genetic/biomarker section; verify indication |
| 70552 | CPT | MRI brain (including brain stem), with contrast | Source groups under genetic/biomarker section; verify indication |
| 70553 | CPT | MRI brain (including brain stem), without and with contrast | Source groups under genetic/biomarker section; verify indication |
| 80428 | CPT | Growth hormone stimulation panel (e.g., arginine infusion, l-dopa administration) | Source groups under genetic/biomarker section; verify indication |
Not Covered / Experimental CPT Codes
| Code | Type | Description | Reason |
|---|---|---|---|
| 0398T | CPT | MRgFUS stereotactic ablation lesion, intracranial | Experimental — alpha-synuclein immunotherapy / robot-assisted gait training group |
| 38232 | CPT | Bone marrow harvesting for transplantation; autologous | Experimental — alpha-synuclein immunotherapy group |
| 38240 | CPT | Hematopoietic progenitor cell; allogeneic transplantation | Experimental — alpha-synuclein immunotherapy group |
| 38241 | CPT | Hematopoietic progenitor cell; autologous transplantation | Experimental — alpha-synuclein immunotherapy group |
| 42400 | CPT | Biopsy of salivary gland; needle (submandibular) | Experimental — alpha-synuclein immunotherapy group |
| 61850 | CPT | Twist drill or burr hole(s) for implantation of neurostimulator electrodes, cortical | Experimental — alpha-synuclein immunotherapy / robot-assisted gait training group |
| 61860 | CPT | Craniectomy or craniotomy for implantation of neurostimulator electrodes, cerebral, cortical | Experimental group |
| 63650 | CPT | Percutaneous implantation of neurostimulator electrode array, epidural | Experimental — PD indication |
| 63655 | CPT | Laminectomy for implantation of neurostimulator electrodes, plate/paddle, epidural | Experimental — PD indication |
| 63661 | CPT | Removal of spinal neurostimulator electrode percutaneous array(s) | Experimental group |
| 63662 | CPT | Removal of spinal neurostimulator electrode plate/paddle(s) via laminotomy or laminectomy | Experimental group |
| 63663 | CPT | Revision/replacement of spinal neurostimulator electrode percutaneous array(s) | Experimental group |
| 63664 | CPT | Revision/replacement of spinal neurostimulator electrode plate/paddle(s) | Experimental group |
| 63685 | CPT | Insertion or replacement of spinal neurostimulator pulse generator or receiver | Experimental group |
| 63688 | CPT | Revision or removal of implanted spinal neurostimulator pulse generator or receiver | Experimental group |
| 64760 | CPT | Transection or avulsion of vagus nerve (vagotomy), abdominal | Experimental — not covered as PD treatment |
| 90867 | CPT | Therapeutic repetitive TMS treatment; planning | Experimental for PD |
| 90868 | CPT | Repetitive TMS; delivery and management, per session | Experimental for PD |
| 90869 | CPT | Repetitive TMS; subsequent delivery and management, per session | Experimental for PD |
| 92270 | CPT | Electro-oculography with interpretation and report | Experimental group |
| 93660 | CPT | Tilt table evaluation with continuous ECG monitoring | Experimental group |
| 93890 | CPT | Transcranial Doppler; vasoreactivity study | Experimental group |
| 95961 | CPT | Functional cortical and subcortical mapping by stimulation/recording of electrodes on brain surface | Experimental group |
| 95962 | CPT | Each additional hour of physician attendance for cortical mapping | Experimental group |
| 95970 | CPT | Electronic analysis of implanted neurostimulator pulse generator system | Experimental group — PD context |
| 95971 | CPT | Simple spinal cord or peripheral neurostimulator analysis | Experimental group — PD context |
| 95972 | CPT | Complex spinal cord or peripheral neurostimulator analysis | Experimental group — PD context |
| 99183 | CPT | Physician attendance and supervision of hyperbaric oxygen therapy, per session | Experimental — not covered for PD |
| 0361U | CPT | Neurofilament light chain, digital immunoassay, plasma, quantitative | Experimental — investigational biomarker |
| 0393U | CPT | Neurology (PD/DLB), CSF, detection of alpha-synuclein | Experimental — investigational |
| 0443U | CPT | Neurofilament light chain (NfL), ultra-sensitive immunoassay, serum or CSF | Experimental — investigational biomarker |
| 0547U | CPT | Neurofilament light chain (NfL), chemiluminescent enzyme immunoassay, plasma, quantitative | Experimental — investigational biomarker |
| 81330 | CPT | SMPD1 gene analysis (Niemann-Pick disease, Type A) | Genetic testing group — condition-specific coverage |
| 81401 | CPT | Molecular pathology procedure level 2 | Not covered for urinary LRRK2 phosphorylation for PD |
| 82013 | CPT | Acetylcholinesterase (salivary biomarker) | Experimental — salivary biomarker |
| 82172 | CPT | Apolipoprotein, each — not covered for APOE | Explicitly excluded |
| 82234 | CPT | Beta-amyloid 1-42 (Abeta 42) | Genetic/biomarker group |
| 82530 | CPT | Cortisol; free (salivary biomarker) | Experimental — salivary biomarker |
| 82533 | CPT | Cortisol; total (salivary biomarker) | Experimental — salivary biomarker |
| 83884 | CPT | Neurofilament light chain (NfL) | Experimental — investigational biomarker |
| 88184 | CPT | Flow cytometry, cell surface/cytoplasmic/nuclear marker; first marker | Experimental group |
| 88185 | CPT | Flow cytometry; each additional marker | Experimental group |
| 88341 | CPT | Immunohistochemistry or immunocytochemistry, per specimen | ICSF alpha-synuclein test — investigational |
| 88342 | CPT | Immunohistochemistry or immunocytochemistry, per specimen | ICSF alpha-synuclein test — investigational |
| 88343 | CPT | Immunohistochemistry or immunocytochemistry, per specimen | ICSF alpha-synuclein test — investigational |
| 88344 | CPT | Immunohistochemistry or immunocytochemistry, per specimen | ICSF alpha-synuclein test — investigational |
| 80349 | CPT | Cannabinoids, natural; synthetic | Related code — verify PD coverage |
| 80350 | CPT | Cannabinoids, natural; synthetic | Related code — verify PD coverage |
| 80351 | CPT | Cannabinoids, natural; synthetic | Related code — verify PD coverage |
| 80352 | CPT | Cannabinoids, natural; synthetic | Related code — verify PD coverage |
Not Covered / Experimental HCPCS Codes
Important note on HCPCS coverage status: The source data groups all HCPCS codes under a single group label in the table structure. The DBS hardware codes (C1607, C1767, C1778, C1787, C1816, C1820, C1822, C1883, C1897) are expected to be covered when the underlying DBS surgical criteria are met — consistent with the covered CPT codes for DBS implantation — but the source does not explicitly separate covered from non-covered HCPCS codes. Confirm individual HCPCS code coverage status with Aetna directly before billing.
| Code | Type | Description | Reason |
|---|---|---|---|
| A4290 | HCPCS | Sacral nerve stimulation test lead, each | Experimental — cueing module / wearable inertial sensor group |
| A4542 | HCPCS | Supplies and accessories for external upper limb tremor stimulator | Experimental group |
| A4575 | HCPCS | Topical hyperbaric oxygen chamber, disposable | Experimental — not covered for PD |
| C1607 | HCPCS | Neurostimulator, integrated (implantable), rechargeable with all components | Expected covered when DBS criteria met; confirm with Aetna — source does not explicitly separate covered/non-covered HCPCS codes |
| C1767 | HCPCS | Generator, neurostimulator (implantable), nonrechargeable | Expected covered when DBS criteria met; confirm with Aetna |
| C1778 | HCPCS | Lead, neurostimulator (implantable) | Expected covered when DBS criteria met; confirm with Aetna |
| C1787 | HCPCS | Patient programmer, neurostimulator | Expected covered when DBS criteria met; confirm with Aetna |
| C1816 | HCPCS | Receiver and/or transmitter, neurostimulator (implantable) | Expected covered when DBS criteria met; confirm with Aetna |
| C1820 | HCPCS | Generator, neurostimulator (implantable), non high frequency with rechargeable battery | Expected covered when DBS criteria met; confirm with Aetna |
| C1822 | HCPCS | Generator, neurostimulator (implantable), high frequency with rechargeable battery | Expected covered when DBS criteria met; confirm with Aetna |
| C1883 | HCPCS | Adaptor/extension, pacing lead or neurostimulator lead (implantable) | Expected covered when DBS criteria met; confirm with Aetna |
| C1897 | HCPCS | Lead, neurostimulator test kit (implantable) | Expected covered when DBS criteria met; confirm with Aetna |
| C9734 | HCPCS | Focused ultrasound ablation/therapeutic intervention with MRI guidance | Experimental for PD indication |
| E0446 | HCPCS | Topical oxygen delivery system, not otherwise specified | Experimental — not covered for PD |
| E0734 | HCPCS | External upper limb tremor stimulator of peripheral nerves of wrist | Experimental group |
| E0745 | HCPCS | Neuromuscular stimulator, electronic shock unit | Experimental group |
Note: No ICD-10-CM codes were provided in the policy data for CPB 0307.
Get the Full Picture for CPT 96132
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.